These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 3143064

  • 1. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
    Garvey J, Petersen M, Waters CM, Rose SP, Hunt S, Briggs R, Jenner P, Marsden CD.
    Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
    [Abstract] [Full Text] [Related]

  • 2. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD.
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [Abstract] [Full Text] [Related]

  • 3. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM, Jackson MJ, Jenner P, Marsden CD.
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [Abstract] [Full Text] [Related]

  • 4. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
    Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, LHeureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A.
    Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
    [Abstract] [Full Text] [Related]

  • 5. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA, Rothblat DS, Joyce JN, Schneider JS.
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
    Jenner P, Rose S, Nomoto M, Marsden CD.
    Adv Neurol; 1987 Jan; 45():183-6. PubMed ID: 2881443
    [No Abstract] [Full Text] [Related]

  • 9. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
    Ueki A, Chong PN, Albanese A, Rose S, Chivers JK, Jenner P, Marsden CD.
    Neuropharmacology; 1989 Oct; 28(10):1089-97. PubMed ID: 2510050
    [Abstract] [Full Text] [Related]

  • 10. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
    Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD.
    Neurosci Lett; 1984 Sep 07; 50(1-3):85-90. PubMed ID: 6436758
    [Abstract] [Full Text] [Related]

  • 11. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M, Stahl S, Jenner P, Marsden CD.
    Mov Disord; 1987 Sep 07; 2(1):37-45. PubMed ID: 2904119
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 14. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS, Bankiewicz KS, Quarantelli M, Plunkett RJ, Frank J, Kopin IJ, Di Chiro G.
    Ann Neurol; 1994 Jun 01; 35(6):689-97. PubMed ID: 8210225
    [Abstract] [Full Text] [Related]

  • 15. Pathology of MPTP in the marmoset.
    Gibb WR, Lees AJ, Wells FR, Barnard RO, Jenner P, Marsden CD.
    Adv Neurol; 1987 Jun 01; 45():187-90. PubMed ID: 3103386
    [No Abstract] [Full Text] [Related]

  • 16. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar 01; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 17. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Allen JM, Cross AJ, Yeats JC, Ghatei MA, McGregor GP, Close SP, Pay S, Marriott AS, Tyers MB, Crow TJ.
    Brain; 1986 Feb 01; 109 ( Pt 1)():143-57. PubMed ID: 2417654
    [Abstract] [Full Text] [Related]

  • 18. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K, Kondo T, Narabayashi H.
    No To Shinkei; 1987 Jul 01; 39(7):663-72. PubMed ID: 3314916
    [Abstract] [Full Text] [Related]

  • 19. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S, Miyoshi R, Mizuno K, Nitta K, Matsubayashi H, Yamamura Y, Tahara E.
    Adv Neurol; 1987 Jul 01; 45():159-65. PubMed ID: 2881441
    [No Abstract] [Full Text] [Related]

  • 20. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
    Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, Oriaku ET, Lamango NS, Soliman KF, Charlton CG.
    Pharmacol Biochem Behav; 2006 Mar 01; 83(3):349-59. PubMed ID: 16580056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.